



Alliance Abstracts at ASCO 2015

Date	Start Time	End Time	Location	Session Type or Speaker / Presenter	Session / Presentation / Abstract Title	Abstract	Poster Board
5/30/2015	8:00 AM	11:30 AM	S Hall A	Poster Session	Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy		
				Hyman B. Muss, MD	Standard chemotherapy versus capecitabine for older women with early stage breast cancer: An update of CALGB/CTSU/Alliance 49907 .	1022	136
				Manish Sharma, MD	A model-based approach to dose optimization of neurotoxic chemotherapy for metastatic breast cancer (MBC).	1041	155
				Judy Caroline Boughey, M.D.	Effect of the use of immediate reconstruction on the rates of bilateral mastectomy and adjuvant radiation therapy use in women with node-positive breast cancer treated with neoadjuvant chemotherapy on ACOSOG Z1071 (Alliance) .	1060	174
5/30/2015	8:00 AM	11:30 AM	S Hall A	Poster Session	Breast Cancer—HER2/ER		
				Keith L. Knutson, PhD	Associations of HER2-specific immunity with survival during treatment with trastuzumab and chemotherapy in breast cancer.	587	76
5/30/2015	1:15 PM	4:15 PM	S100bc	Oral Abstract Session	Cancer Prevention, Genetics, and Epidemiology		
	3:39 PM	3:51 PM		Amanda I. Phipps, PhD	Alcohol consumption and prognosis in patients with stage III colon cancer: A correlative analysis of phase III trial NCCTG N0147 (Alliance) .	1508	
5/30/2015	1:15 PM	4:15 PM	S102	Oral Abstract Session	Health Services Research and Quality of Care		
	2:27 PM	2:39 PM		Deborah Schrag, MD, MPH	Cost of chemotherapy for metastatic colorectal cancer with either bevacizumab or cetuximab: Economic analysis of CALGB/SWOG 80405 .	6504	
5/30/2015	1:15 PM	4:45 PM	S Hall A	Poster Session	Patient and Survivor Care		
				Thomas Michael Atkinson, PhD	Comparison between clinician- and patient-reporting of baseline (BL) and post-BL symptomatic toxicities in cancer cooperative group clinical trials (NCCTG N0591 [Alliance]).	9520	179
				Kathryn Jean Ruddy, MD, MPH	A comparison of the natural history of oxaliplatin- and paclitaxel-induced neuropathy (NCCTG N08C1, N08CB/Alliance).	9564	223
5/30/2015	1:15 PM	4:45 PM	S Hall A	Poster Session	Head and Neck Cancer		
				Alan Loh Ho, MD, PhD	Alliance A091104 : A phase II trial of MK-2206 in patients (pts) with progressive, recurrent/metastatic adenoid cystic carcinoma.	6039	362

Date	Start Time	End Time	Location	Session Type or Speaker / Presenter	Session / Presentation / Abstract Title	Abstract	Poster Board
5/30/2015	3:00 PM	6:00 PM	E Hall D2	Oral Abstract Session	Gastrointestinal (Colorectal) Cancer		
	4:00 PM	4:12 PM		Kimmie Ng, MD, MPH	Vitamin D status and survival of metastatic colorectal cancer patients: Results from CALGB/SWOG 80405 (Alliance).	3503	
	5:00 PM	5:12 PM		Aziz Zaanan, MD, PhD	Analysis of DNA mismatch repair (MMR) and clinical outcome in stage III colon cancers from patients (pts) treated with adjuvant FOLFOX +/- cetuximab in the PETACC8 and NCCTG N0147 adjuvant trials.	3506	
	5:12 PM	5:24 PM		Julien Taieb, MD, PhD	Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX +/- cetuximab: A pooled analysis of 3934 pts from the PETACC8 and N0147 trials.	3507	
5/31/2015	8:00 AM	11:00 AM	E Hall D2	Oral Abstract Session	Gastrointestinal (Noncolorectal) Cancer		
	9:24 AM	9:36 AM		Matthew H. Kulke, MD	Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance).	4005	
	10:24 AM	10:36 AM		Matthew H. G. Katz, MD	Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): Initial results from Alliance Trial A021101.	4008	
5/31/2015	8:00 AM	11:30 AM	S Hall A	Poster Session	Lymphoma and Plasma Cell Disorders		
				Patrick B. Johnston, MD, PhD	Combination of everolimus with R-CHOP (ever R-CHOP) as an initial therapy for diffuse large B-cell lymphoma (DLBCL): A phase I and feasibility study (NCCTG N1085 [Alliance]).	8518	335
				Sarah A. Holstein, MD, PhD	Updated analysis of CALGB/ECOG/BMT CTN 100104: Lenalidomide (Len) vs. placebo (PBO) maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma (MM).	8523	340
				Grzegorz S. Nowakowski, MD	Bendamustine and rituximab and lenalidomide (BRR) in the treatment of relapsed and refractory low grade non-Hodgkin lymphoma (NHL): Final results of phase 1 study NCCTG N1088/ALLIANCE.	8540	357
5/31/2015	1:00 PM	4:00 PM	N Hall B1	Plenary Session	Plenary Session Including the Science of Oncology Award and Lecture		
	3:05 PM	3:20 PM		Paul D. Brown, MD	NCCTG N0574 (Alliance): A phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases.	LBA4	
6/1/2015	8:00 AM	11:00 AM	N Hall B1	Oral Abstract Session	Breast Cancer—HER2/ER		
	8:12 AM	8:24 AM		Maura N. Dickler, MD	Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance).	501	
6/1/2015	8:00 AM	11:00 AM	S102	Oral Abstract Session	Patient and Survivor Care		
	8:12 AM	8:24 AM		Andrew Louis Himelstein, MD, FACP	CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer.	9501	

Date	Start Time	End Time	Location	Session Type or Speaker / Presenter	Session / Presentation / Abstract Title	Abstract	Poster Board
6/1/2015	8:00 AM	11:30 AM	S Hall A	Poster Session	Gastrointestinal (Colorectal) Cancer		
				Preet Paul Singh, MD	Relationship between metformin use and recurrence and survival in patients (pts) with resected stage III colon cancer (CC) receiving adjuvant chemotherapy: Results from NCCTG N0147 (Alliance) .	3531	23
				Volker Heinemann, MD, PhD	Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405 .	3585	78
				Ryan Eldredge Wilcox, MD	Influence of molecular alterations on site-specific (ss) time to recurrence (TTR) following adjuvant therapy in resected colon cancer (CC) (Alliance Trial N0147).	3590	83
				Federico Innocenti, MD, PhD	A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405 .	3599	92
6/1/2015	8:00 AM	11:30 AM	S Hall A	Poster Session	Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers		
				David E. Gerber, MD	ALCHEMIST : a clinical trial platform to bring genomic discovery and molecularly targeted therapies to early-stage lung cancer.	TPS7583	331a
6/1/2015	1:15 PM	4:45 PM	S Hall A	Poster Session	Central Nervous System Tumors		
				Nadia N. Laack, MD, MS	Randomized, placebo-controlled, phase II study of dasatinib with standard chemo-radiotherapy for newly diagnosed glioblastoma (GBM), NCCTG N0877 (Alliance) .	2013	2
6/1/2015	1:15 PM	4:45 PM	S Hall A	Poster Session	Melanoma/Skin Cancers		
				Jason John Luke, MD, FACP	Randomized phase II study comparing the MET inhibitor cabozantinib to temozolomide (TMZ) or dacarbazine (DTIC) in ocular melanoma: A091201 .	TPS9087	326a
6/1/2015	3:00 PM	6:00 PM	N Hall B1	Oral Abstract Session	Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy		
	5:12 PM	5:24 PM		Mehra Golshan, MD	Impact of neoadjuvant therapy on breast conservation rates in triple-negative and HER2-positive breast cancer: Combined results of CALGB 40603 and 40601 (Alliance) .	1007	
6/2/2015	8:00 AM	11:00 AM	S404	Oral Abstract Session	Central Nervous System Tumors		
	9:12 AM	9:24 AM		Evanthia Galanis, MD	NCCTG N0872 (Alliance) : A randomized placebo-controlled phase II trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma (GBM).	2004	
Published but not presented							
				Collin Thomas Zimmerman	Venlafaxine to prevent oxaliplatin-induced neuropathy?: A pilot randomized placebo-controlled trial.	e20734	
				Rui Qin	Quality of life analysis of NCCTG N0877 (Alliance) : Phase II trial of either dasatinib or placebo combined with standard chemoradiotherapy for newly diagnosed glioblastoma multiforme (GBM).	e17715	

Other NCTN Abstracts with Alliance Participation at ASCO 2015

Date	Start Time	End Time	Location	Session Type or Speaker / Presenter	Session / Presentation / Abstract Title	Abstract	Poster Board
5/30/2015	8:00 AM	11:30 AM	S Hall A	Poster Session	Breast Cancer—HER2/ER		
				Maria M Zlobinsky Rubinstein	Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity.	533	21
5/31/2015	8:00 AM	11:00 AM	E Hall D2	Oral Abstract Session	Gastrointestinal (Noncolorectal) Cancer		
				Mariana Chavez-Mac Gregor, MD, MSc	Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor (HR) positive and HER2-negative breast cancer (BC): SWOG/NRG/Alliance S1207 (NCT01674140).	TPS637	120a
5/31/2015	8:00 AM	11:30 AM	S Hall A	Poster Session	Leukemia, Myelodysplasia, and Transplantation		
				James C. Yao, MD	SWOG S0518: Phase III prospective randomized comparison of depot octreotide plus interferon alpha-2b versus depot octreotide plus bevacizumab (NSC #704865) in advanced, poor prognosis carcinoid patients (NCT00569127).	4004	
6/1/2015	8:00 AM	11:00 AM	N Hall B1	Oral Abstract Session	Breast Cancer—HER2/ER		
				Jeffrey E. Lancet, MD	Safety and tolerability of the combination of ATRA + arsenic trioxide (ATO) + gemtuzumab ozogamicin (GO) in high-risk acute promyelocytic leukemia (APL): Initial report of the SWOG/Alliance/ECOG S0535 trial.	7016	6
6/1/2015	8:00 AM	11:30 AM	S Hall A	Poster Session	Gastrointestinal (Noncolorectal) Cancer		
				Julie Gralow, MD	Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307.	503	
6/1/2015	8:00 AM	11:30 AM	S Hall A	Poster Session	Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers		
				Vincent M. Chung, MD	SWOG S1115: Randomized phase II trial of selumetinib (AZD6244; ARRY 142886) hydrogen sulfate (NSC-748727) and MK-2206 (NSC-749607) vs. mFOLFOX in pretreated patients (Pts) with metastatic pancreatic cancer.	4119	231
6/1/2015	8:00 AM	11:30 AM	S Hall A	Poster Session	Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers		
				Pamela L. Kunz, MD	A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).	TPS4145	250b
6/1/2015	8:00 AM	11:30 AM	S Hall A	Poster Session	Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers		
				David E. Gerber, MD	ALCHEMIST: a clinical trial platform to bring genomic discovery and molecularly targeted therapies to early-stage lung cancer.	TPS7583	331a